Benitec Biopharma Limited Stock Forecast NASDAQ:BNTC

Price Target and Analyst Ratings

Most Recent Rating

LADENBURG THALM/SH SH is very positive about BNTC and gave it a "Buy" rating on April 20, 2020. The price target was set to $14.00.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2020-10-05	Buy - Neutral	Downgraded by	LADENBURG THALM/SH SH	$3.20
2020-04-20	Buy	Initiated by	LADENBURG THALM/SH SH	$13.06	$14.00

BNTC Stock Trend

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -3.96% during the next 3 months and, with a 90% probability hold a price between $3.27 and $4.06 at the end of this 3-month period.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-20	$3.40	$3.81	$4.22
2021-09-21	$3.40	$3.81	$4.22
2021-09-22	$3.39	$3.81	$4.22
2021-09-23	$3.39	$3.80	$4.22
2021-09-24	$3.39	$3.80	$4.21
2021-09-27	$3.39	$3.80	$4.21
2021-09-28	$3.38	$3.79	$4.21
2021-09-29	$3.38	$3.79	$4.20
2021-09-30	$3.38	$3.79	$4.20
2021-10-01	$3.37	$3.79	$4.20
2021-10-04	$3.37	$3.78	$4.20
2021-10-05	$3.37	$3.78	$4.19
2021-10-06	$3.37	$3.78	$4.19
2021-10-07	$3.36	$3.78	$4.19
2021-10-08	$3.36	$3.77	$4.19
2021-10-11	$3.36	$3.77	$4.18
2021-10-12	$3.35	$3.77	$4.18
2021-10-13	$3.35	$3.76	$4.18
2021-10-14	$3.35	$3.76	$4.17
2021-10-15	$3.35	$3.76	$4.17
2021-10-18	$3.34	$3.76	$4.17
2021-10-19	$3.34	$3.75	$4.17
2021-10-20	$3.34	$3.75	$4.16
2021-10-21	$3.34	$3.75	$4.16
2021-10-22	$3.33	$3.75	$4.16
2021-10-25	$3.33	$3.74	$4.16
2021-10-26	$3.33	$3.74	$4.15
2021-10-27	$3.32	$3.74	$4.15
2021-10-28	$3.32	$3.73	$4.15
2021-10-29	$3.32	$3.73	$4.14

About Benitec Biopharma Limited

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing technology, DNA-directed RNA interference (ddRNAi) in Australia. Its in-house development programs include TT-034, which is in Phase I/IIa clinical trials for the treatment of hepatitis C; Hepbarna for the treatment of the hepatitis B virus; Tribetarna for treating drug resistant non-small cell lung c... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!